ADCT-301: a phase 1 study testing a new drug, ADCT-301, for people whose Hodgkin or non-Hodgkin lymphoma has come back or has not responded to treatment

Recruitment for this trial is temporarily closed.

This is a phase 1 (early phase) trial of an experimental treatment. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment but the trial will give important information about this new treatment, which could help other people in the future.

Purpose of trial

The aim of this trial is to find out more about a new treatment called ADCT-301 for Hodgkin and non-Hodgkin lymphoma. It is for people with lymphoma that has relapsed (come back) or is refractory (not responding) to treatment. It aims to find:

  • the best dose to use 
  • more about the side effects
  • how well the treatment works
  • how the treatment behaves in the body.


This trial is looking at a treatment called ADCT-301. ADCT-301 is made up of an antibody joined to a drug that kills lymphoma cells. This type of treatment is called an 'antibody-drug conjugate'. The antibody targets a protein found on the surface of many lymphoma cells, called CD25. The antibody carries the drug to the lymphoma cells wherever they are in the body.

You have the treatment intravenously (through a drip into your vein) once every 3 weeks.

This trial is in two parts:

  • Part 1 is to find out the highest safe dose of the treatment. This is done by ‘dose escalation’. Participants are treated in groups of three. The first three participants have the lowest dose. The next three have a higher dose. This continues and everyone taking part is monitored closely for side effects. The highest dose that doesn’t cause serious side effects is used in part 2 of the trial.
  • Part 2 is to test how well the highest safe dose of the study treatment works. People entering this part of the trial all have the same dose of the study treatment.

How long you have the treatment for depends on how well it works and on the side effects you have. You can continue to have the treatment for as long as your lymphoma responds to it.

Who can enter

Your consultant can give you advice on whether this trial might be suitable for you.

90 people are needed for this trial.

You may be able to enter if:

  • You have Hodgkin or non-Hodgkin lymphoma that has come back or has not responded to treatment.
  • Your lymphoma is measurable by the tests used in the trial.
  • You are well enough to look after yourself and are up and about more than 50% of your waking hours, even if you are not well enough to work.
  • You and your partner are willing to use reliable contraception if there is any chance of you or your partner becoming pregnant.
  • You agree to have a pregnancy test a week before starting treatment if there is any chance that you could be pregnant.
  • Your blood and other health test results are satisfactory.
  • You have previously had at least one course of treatment for your lymphoma.
  • You are over 18.

You will not be able to enter if:

  • There is any existing standard treatment available for your lymphoma that you haven’t already had.
  • You still have significant side effects from your previous treatment.
  • You have a complication of previous treatment called graft versus host disease
  • You have any health problems that your doctor thinks might make it unsafe for you to have the trial treatment.
  • You have had any autoimmune disease or conditions called Steven’s Johnson’s syndrome or toxic epidermal necrolysis syndrome in the past.
  • You’ve had major surgery, radiotherapy or other cancer treatment (including other trial treatments) within 2 weeks of starting treatment in this trial.
  • You are taking steroids within 4 weeks of starting treatment in this trial.
  • You have HIV, Hepatitis C virus or Hepatitis B virus.
  • You have another type of cancer, except certain localised cancers.
  • You are pregnant or breastfeeding.
  • The study treatment is not suitable for you.

Further information

More information about this trial is available at